Johnson & Johnson (JNJ)vsNewGenIvf Group Limited Class A Ordinary Shares (NIVF)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
NIVF
NewGenIvf Group Limited Class A Ordinary Shares
$1.72
-6.01%
HEALTHCARE · Cap: $1.11M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 2038703% more annual revenue ($96.36B vs $4.73M). NIVF leads profitability with a 209.0% profit margin vs 21.8%. NIVF trades at a lower P/E of 0.1x. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
NIVF
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Intrinsic value data unavailable for NIVF.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 79 in profit
Keeps 209 of every $100 in revenue as profit
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of -349.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : NIVF
The strongest argument for NIVF centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 209.0% and operating margin at -349.1%. Revenue growth of 11.9% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : NIVF
The primary concerns for NIVF are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
JNJ carries more volatility with a beta of 0.33 — expect wider price swings.
NIVF is growing revenue faster at 11.9% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (59/100 vs 57/100), backed by strong 21.8% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →NewGenIvf Group Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL CARE FACILITIES · USA
NewGenIvf Group Limited (NIVF) is a leading entity in the reproductive health industry, focusing on cutting-edge fertility solutions and sophisticated in vitro fertilization (IVF) services. With a commitment to increasing success rates in assisted reproductive techniques, NIVF is strategically positioned to meet the rising global demand for fertility treatments through an established clinic network and key partnerships. As the market for fertility services continues to expand, the company is poised for significant growth, reinforcing its dedication to helping individuals and couples achieve their aspirations of parenthood.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?